Intellia to Unveil Long-Awaited Phase 3 Data on CRISPR Therapy for Hereditary Angioedema at EAACI Congress
Intellia Therapeutics announced it will present results from the global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z), the first in vivo CRISPR therapy for hereditary angioedema. The data will be shared as a late-breaking presentation on June 13 at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Istanbul.
One Shot That Rewrites the Rules: Why HAELO Changes Everything—and Guarantees Nothing
[The Core]: What’s Really Happening
On June 13, 2026, in Istanbul, Danny Cohn from the University of Amsterdam will step onto the EAACI stage and deliver results the pharmaceutical world has awaited for three years. Intellia Therapeutics will finally release the full Phase 3 HAELO findings for lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002)—the world’s first in vivo CRISPR therapy for hereditary angioedema. Yet the real story lies behind the headlines.
Key figures from the April press release are already public: an 87% reduction in attack frequency versus placebo. Mean monthly attacks fell to 0.26 compared with 2.10. Sixty-two percent of patients remained attack-free and required no prophylactic therapy six months after a single infusion. These numbers don’t just look good—they render weekly injections and daily pills obsolete.
The real drama, however, isn’t efficacy. It’s what’s unfolding behind the scenes. Intellia has already begun a rolling BLA submission to the FDA under RMAT designation, targeting approval in the first half of 2027 and a U.S. launch. In April 2026 the company raised an additional $180 million at $10.75 per share. The stock dropped 15% on the positive Phase 3 news. That reaction only makes sense once you understand how biotech investing actually works.
Timeline and Context
NTLA-2002 is a systemically delivered CRISPR-Cas9 therapy packaged in lipid nanoparticles that knocks out the KLKB1 gene in the liver. No DNA cuts, no viral vectors—just one intravenous infusion that stops liver cells from producing kallikrein, the trigger protein for the bradykinin cascade that causes swelling. Elegant. Potentially lifelong control after a single shot.
The Phase 1/2 study published in NEJM in 2025 showed 75–77% attack reduction at the 50 mg dose. The real shock came at EAACI 2025, when Intellia presented three-year data: 98% attack reduction, all ten patients attack-free and off therapy for an average of 23 months, with no serious adverse events and only mild, transient infusion reactions.
Phase 3 HAELO, a randomized, double-blind, placebo-controlled trial, began in January 2025 and completed enrollment early. April 2026 brought the topline readout: primary and all key secondary endpoints met. Sixty-two percent of patients were attack-free and off therapy at six months versus 11% on placebo—an 87% reduction in attacks.
In June 2026 Intellia promises “additional data” at EAACI. The real question is what those extras will include. Most likely subgroup analyses, quality-of-life metrics, and more granular safety details. The potential blockbuster would be long-term follow-up from the first Phase 3 cohort—if efficacy holds at 12 months or beyond without waning.
Winners and Losers
Biggest loser #1: Takeda and Takhzyro (lanadelumab). The current market leader in HAE prophylaxis generates roughly $1.5 billion annually, requires subcutaneous injections every two weeks or monthly, and still demands lifelong adherence. Lonvo-z offers one dose and done. Takeda cannot compete with that model even at a lower price.
Runner-up #2: Ionis Pharmaceuticals with Dawnzera (donidalorsen). Approved in August 2025, it cuts attacks by more than 90% but still requires injections every four to eight weeks. Patients who stay attack-free for a year after one infusion are unlikely to return to regular shots.
Runner-up #3: CSL Behring with Andembry (garadacimab). Approved June 2025, monthly injections, 99% attack reduction—yet another excellent therapy rendered technologically dated the moment lonvo-z reaches the market.
Biggest winner #1: HAE patients. Roughly 50,000 worldwide, 7,000 diagnosed in the United States. Current options mean daily pills or regular injections. Lonvo-z offers the possibility of functional cure—attack-free without ongoing therapy.
Biggest winner #2: Intellia Therapeutics—if everything goes to plan. The company posted a $96.23 million net loss in Q1 2026 and raised fresh capital because commercialization will require still more investment. Peak sales could reach $1–2 billion annually, but not before 2028.
What the Media Isn’t Saying
First insight: shares fell 15% after positive Phase 3 data and the equity raise because investors focused on dilution and the long, expensive road to commercialization. The $180 million raise at $10.75 created roughly 17 million new shares.
Second insight: U.S. payers are already bracing for a $500,000–$1,000,000 one-time price tag. They dislike large upfront outlays even when lifetime economics favor the therapy. Risk-sharing agreements and deferred-payment structures will be essential.
Third insight: oral sebetralstat (KalVista, approved July 2025) remains an attractive on-demand option for patients with infrequent attacks who prefer to treat only when symptoms appear.
Fourth insight: 38% of Phase 3 patients still experienced attacks. Intellia will need strategies for incomplete responders, including possible redosing or combination approaches.
Outlook: Next 30 and 90 Days
Next 30 days (end of June 2026): EAACI presentation and market reaction.
Expect long-term follow-up (9–12 months), subgroup analyses by HAE type, and detailed safety data. Strong 12-month results could lift shares 20–30%. Any sign of waning efficacy would trigger a sharp sell-off.
Next 90 days (September 2026): Battle over label language.
The pivotal question is whether regulators approve lonvo-z for all HAE patients or restrict it to refractory cases. A narrow label would cap the market at 20–30% of patients. Intellia is expected to announce a commercialization partnership with a major pharma company—candidates include Pfizer, Novartis, or even Takeda.
Finally, success with lonvo-z could revive interest in the company’s paused nex-z program for transthyretin amyloidosis. Failure or additional study requirements would leave Intellia with one drug in launch mode, another on hold, and limited cash. That tension explains why investors remain nervous despite the stellar HAELO numbers. In biotech, nothing is ever simple.
— Editorial Team
